Date: 2013-09-26
Type of information: Production agreement
Compound: HEMO2life®
Company: LFB Biomanufacturing, Laboratoire français du fractionnement et des biotechnologies (France) Hemarina (France)
Therapeutic area: Transplantation
Type agreement: bioproduction
manufacturing
Action mechanism: HEMO2life® enables preservation of organs and tissues under optimal physiological conditions due to oxygen contribution essential to their survival. Indeed, once the organ is removed from the donor it will go through an ischaemia/reperfusion cycle that could induce lesions and graft failures after transplant. HEMO2life® can make up for these two major issues during transplant as an oxygen carrier is facing free radicals during reperfusion. Pre-clinical results have been published in the American Journal of Transplantation (2011; 11: 1845–1860) and showed the graft preservation with HEMO2life®, compared with clinical use solutions, induces fast resumption of normal function and extended preservation time on renal cellular model.
Disease:
Details: * On September 26, 2013, Hemarina, a French based marine biotechnology company dedicated to the R&D of universal oxygen carrier solutions, has signed an industrial subcontracting agreement with LFB Biomanufacturing, LFB group’s subsidiary specialized in the manufacturing of active protein solutions for pharmaceutical applications, leading up to the preparation of HEMO2life® regulatory batches. The first batches of this extraction hemoglobin will be issued at the end of 2013 and the beginning of 2014 from Alès plant (Gard).
Financial terms:
Latest news:
